Mechanism of action
Sonrotoclax is an inhibitor of B-cell lymphoma 2 (BCL-2) protein.
General use cases
- adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
